|  |  |  |
| --- | --- | --- |
|  | Treatment | P |
| Adverse Events | BCG | Epirubicin | Total |
| None | 66 (72.5%) | 15(88.2%) | 81(75%) | 0.308 |
| Dysuria | 17(18.7%) | 2(11.8%) | 19(17.6%) |
| Microscopic Hematuria | 0(0%) | 8(8.8%) | 8(7.4%) |

Supplementary Material Tables. Treatment Adverse Events